Ardelyx (ARDX) Stock Overview
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ARDX from our risk checks.
ARDX Community Fair Values
Create NarrativeSee what 93 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ardelyx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.22 |
| 52 Week High | US$7.18 |
| 52 Week Low | US$3.21 |
| Beta | 0.60 |
| 1 Month Change | 14.36% |
| 3 Month Change | -23.34% |
| 1 Year Change | -23.55% |
| 3 Year Change | 511.95% |
| 5 Year Change | -25.70% |
| Change since IPO | -70.09% |
Recent News & Updates
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise
Jul 11
Ardelyx: 'Hold' With Caution As Major Inflection Point Approaches
Jul 03Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet
May 15Recent updates
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise
Jul 11Ardelyx: 'Hold' With Caution As Major Inflection Point Approaches
Jul 03Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet
May 15
Omnichannel Investments And Sales Teams Will Create Future IBSRELA Demand
Strategic investments and an expanded sales team are expected to drive demand for IBSRELA, boosting revenue and market share.Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Feb 24There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues
Feb 17Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
Dec 20Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Nov 24Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Nov 14Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
Oct 24Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Aug 25Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 07Ardelyx Faces Rising Challenges Despite Revenue Growth
Aug 05Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Jul 13Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
Jul 05Ardelyx: Strong Execution, Fairly Valued
May 10Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
May 03Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 03Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
Jul 31Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now
Apr 17Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Mar 30Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Dec 14Shareholder Returns
| ARDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -0.09% | 0.8% |
| 1Y | -23.6% | -11.7% | 17.5% |
Return vs Industry: ARDX underperformed the US Biotechs industry which returned -11.7% over the past year.
Return vs Market: ARDX underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| ARDX volatility | |
|---|---|
| ARDX Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARDX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 395 | Mike Raab | www.ardelyx.com |
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Ardelyx, Inc. Fundamentals Summary
| ARDX fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$53.76m |
| Revenue (TTM) | US$361.71m |
Is ARDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARDX income statement (TTM) | |
|---|---|
| Revenue | US$361.71m |
| Cost of Revenue | US$112.41m |
| Gross Profit | US$249.30m |
| Other Expenses | US$303.06m |
| Earnings | -US$53.76m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 04, 2025
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 68.92% |
| Net Profit Margin | -14.86% |
| Debt/Equity Ratio | 122.1% |
How did ARDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/29 22:47 |
| End of Day Share Price | 2025/07/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ardelyx, Inc. is covered by 20 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |